Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 8,81€(+29,37%). Der Median liegt bei 8,53€(+25,26%).
Kaufen | 4 |
Halten | 6 |
Verkaufen | 2 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company's previously announced $16 million offering that was announced on May 15, 2025. The o.» Mehr auf businesswire.com
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2025 and business updates. “We are pleased that we have secured additional financing that is expected to extend our cash runway through the first quarter of 2026,” sai.» Mehr auf businesswire.com
Atara Biotherapeutics Announces Pricing of $16 Million Offering
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the pricing of an offering of 834,237 shares of its common stock at an offering price of $6.61 per share and pre-funded warrants to purchase 1,587,108 shares of its common stock at an offering price of $6.6.» Mehr auf businesswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 90,72 Mio | 257,91% |
Bruttoeinkommen | 71,83 Mio | 205,55% |
Nettoeinkommen | 35,13 Mio | 111,94% |
EBITDA | 37,73 Mio | 239,54% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 46,16 Mio€ |
Anzahl Aktien | 6,80 Mio |
52 Wochen-Hoch/Tief | 15,96€ - 4,27€ |
Dividenden | Nein |
Beta | 0,18 |
KGV (PE Ratio) | −5,48 |
KGWV (PEG Ratio) | −0,08 |
KBV (PB Ratio) | −1,56 |
KUV (PS Ratio) | 0,53 |
Unternehmensprofil
Name | Atara Biotherapeutics Inc |
CEO | Anhco Nguyen |
Mitarbeiter | 153 |
Assets entdecken
Shareholder von Atara Biotherapeutics Inc investieren auch in folgende Assets